HIGHLIGHTS
As expected, ticagrelor reduced ex-vivo ADP-induced aggregation in patients with pneumonia compared with placebo.
Ticagrelor reduced platelet-leukocyte interactions as well as plasma interleukin-6 within 24 h in patients with pneumonia compared with placebo.
Ticagrelor acutely altered NETosis biomarkers, whereas placebo had no effect.
Ticagrelor improved lung function and and severity of community-acquired pneumonia (CAP) reported trends toward reduced instances of mechanical ventilation, mortality, and the composite endpoint of death in CAP inpatients (13) . Similarly, an observational study of 224 hospitalized CAP patients showed lower use of intensive care unit care in patients receiving antiplatelet agents for at least 6 months compared with unmatched controls (14) . A study of 615 patients consecutively admitted to medical and surgical intensive care units found that use of antiplatelet agents was associated with reductions in mortality and attenuation in thrombocytopenia (15 (17) .
Taken together, these observations suggest that antiplatelet therapy may improve outcomes in ambulatory patients with pneumonia, and potentially in sepsis. The mechanism for a beneficial effect could be multifactorial. Platelet activation is associated with worse cardiovascular outcomes in patients with pneumonia (2) . Platelet activation results in adhesion, the expression of cell surface receptors, and the release of small molecules that can promote thrombosis and amplify the immune response. Specifically, platelet activation results in expression of P-selectin, increases platelet-leukocyte aggregates, and triggers the formation of neutrophil extracellular DNA nets. Platelet-leukocyte aggregates predict mortality in severe sepsis (18) , and DNA nets associate with severity of sepsis and septic organ dysfunction (19) . In animals, platelets and neutrophils accumulate in lungs in models of sepsis, during both bacterial and viral infection (20) . Furthermore, Sexton et al.
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antagonist upon enrollment were not included on the analysis of flow cytometry, platelet function, biomarker analysis, and spirometry.
The XANTHIPPE trial was a double-blind study in which subjects were randomized to placebo or ticagrelor (180-mg loading dose followed by 90 mg twice a day) for up to 7 days or until discharge from the hospital. Randomization and drug distribution were Ex vivo platelet aggregation using platelet-rich plasma (PRP) and whole blood was performed as previously described (22) . Aggregation with PRP prepared from citrated blood was determined using a light transmission aggregometer (Chrono-log Corp.,
Havertown, Pennsylvania). PRP was incubated at 37 C Abbreviations as in Table 1 .
Sexton et al.
Ticagrelor in the Setting of Pneumonia Louis, Missouri). Mice were assessed every 12 h for 5
days. Blood was collected at the indicated time points after LPS injection, and plasma was prepared by 
centrifugation. TNF-a and IL-6 were measured by ELISA assay (eBioscience, San Diego, California).
DETERMINATION OF PULMONARY MICROVASCULAR
PERMEABILITY. Lungs were isolated 6 h after injection of LPS and microvessel capillary filtration coefficient (K fc ) was measured as described previously (23) . In brief, after 20-min equilibration perfusion to establish an isogravimetric condition, the outflow 
.3 (R Project for Statistical
Computing, Vienna, Austria). Graphs in figures were generated in SigmaPlot version 13.0.
RESULTS

TICAGRELOR MODULATES INFLAMMATORY RESPONSE IN PATIENTS HOSPITALIZED WITH
PNEUMONIA. To evaluate the effect of the direct acting P2Y 12 antagonist ticagrelor in pneumonia, we randomized patients hospitalized within 48 h of diagnosis to receive placebo or ticagrelor for up to 7 days. Table 2 lists demographic and baseline characteristics of patients enrolled in the XANTHIPPE trial.
The average age was 55.1 AE 16.0 years in the placebo group (53% female) and 56.6 AE 15.9 years in the ticagrelor group (57% female). There were no significant differences in history of hypertension, smoking history, diabetes, and COPD between the 2 groups. There was no significant difference between the 2 groups with regard to aspirin use before enrollment. There were no significant differences in antibiotic treatment at the time of enrollment between the 2 groups.
Twenty-one subjects were diagnosed with CAP in the placebo arm (70%) and 17 subjects in the ticagrelor arm (57%) ( Table 3) . At 30 days, there were a total of 7 rehospitalizations (4 in the placebo group and 3 in the ticagrelor group) and 3 deaths (3 in the placebo group and 0 in the ticagrelor group). No major bleeding occurred in any of the patients.
No significant differences in platelet or white blood cell counts were observed in the 2 groups at baseline or at 24 h after intervention ( Table 3) . At baseline, Sexton et al.
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Ticagrelor in the Setting of Pneumonia and Sepsis The delta change at 24 and 48 h after dosing for the MPO-NE NETosis assay (A) and circulating dsDNA (B) were measured in placebo patients (open circles) and ticagrelor patients (filled circles) that had samples through 48 h after dosing. Significant changes are indicated by an asterisk. dsDNA ¼ doubled-stranded DNA; MPO ¼ myeloperoxidase;
NE ¼ neutrophil elastase.
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1.15) compared with no change in placebo patients
(OR: 0.99; 95% CI: 0.95 to 1.04) ( Figure 5 ). STUDY LIMITATIONS. The XANTHIPPE study was a prospective study designed to target pneumonia patients. Due to a combination of pneumonia patients having the capacity to consent as well as exclusion criteria, the recruited population was less sick than we had anticipated. We also acknowledge that cecal ligation and puncture model of sepsis may carry more clinical relevance than the endotoxin model that was employed; however, the inflamma- 
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